Tweet
Hum Vaccin Immunother
. 2026 Dec;22(1):2628383.
doi: 10.1080/21645515.2026.2628383. Epub 2026 Feb 12.
Expert opinion on improving influenza vaccination coverage rate in Qatar: Strategic solutions and role of live attenuated influenza vaccine (LAIV)
Muna Al-Maslamani 1 2 , George Kassianos 3 , Khalid El Awad 4 , Eman Al Maslamani 5 6 , Mohammed Alkuwari 7 , Salah Al Awaidy 8 , Peter V Coyle 9 , Manasik Hassan 10 , Hayat S Khogali 4 , Samina Hasnain 4 , Hadi M Yassine 11 , Ahmed Abushahin 6
Affiliations
Seasonal influenza remains a major public health challenge in Qatar, causing significant morbidity and mortality among high-risk groups. Despite annual campaigns and free vaccines, coverage-rate is low, especially among children, the elderly, and pregnant women. This expert opinion review highlights vaccine-related epidemiological trends and barriers to uptake, including hesitancy, limited public awareness, logistical issues, and gaps in healthcare provider education in Qatar region. The panel underscores the urgent need for robust public education, targeted outreach, and empowering healthcare professionals to improve vaccine uptake. Special emphasis is placed on the role of live-attenuated-influenza-vaccine (LAIV), which allows needle-free administration, enhanced immunogenicity, and is suitable for school-based programs. Recommendations include expanding access via mobile clinics and schools, aligning procurement with seasonal peaks, and strengthening surveillance and quality systems. Adopting these strategies and empowering healthcare providers with necessary tools and knowledge can significantly improve influenza vaccination-coverage in Qatar and reinforce long-term public health resilience.
Keywords: Influenza; Qatar; live attenuated influenza vaccine; public health; surveillance; vaccination coverage; vaccine hesitancy.
. 2026 Dec;22(1):2628383.
doi: 10.1080/21645515.2026.2628383. Epub 2026 Feb 12.
Expert opinion on improving influenza vaccination coverage rate in Qatar: Strategic solutions and role of live attenuated influenza vaccine (LAIV)
Muna Al-Maslamani 1 2 , George Kassianos 3 , Khalid El Awad 4 , Eman Al Maslamani 5 6 , Mohammed Alkuwari 7 , Salah Al Awaidy 8 , Peter V Coyle 9 , Manasik Hassan 10 , Hayat S Khogali 4 , Samina Hasnain 4 , Hadi M Yassine 11 , Ahmed Abushahin 6
Affiliations
- PMID: 41679979
- DOI: 10.1080/21645515.2026.2628383
Seasonal influenza remains a major public health challenge in Qatar, causing significant morbidity and mortality among high-risk groups. Despite annual campaigns and free vaccines, coverage-rate is low, especially among children, the elderly, and pregnant women. This expert opinion review highlights vaccine-related epidemiological trends and barriers to uptake, including hesitancy, limited public awareness, logistical issues, and gaps in healthcare provider education in Qatar region. The panel underscores the urgent need for robust public education, targeted outreach, and empowering healthcare professionals to improve vaccine uptake. Special emphasis is placed on the role of live-attenuated-influenza-vaccine (LAIV), which allows needle-free administration, enhanced immunogenicity, and is suitable for school-based programs. Recommendations include expanding access via mobile clinics and schools, aligning procurement with seasonal peaks, and strengthening surveillance and quality systems. Adopting these strategies and empowering healthcare providers with necessary tools and knowledge can significantly improve influenza vaccination-coverage in Qatar and reinforce long-term public health resilience.
Keywords: Influenza; Qatar; live attenuated influenza vaccine; public health; surveillance; vaccination coverage; vaccine hesitancy.